RE:ObviouslyRecall that they entered into Phase II with around $10 million CDN which was to pay for the entire study and the beginning of Phase I for GBM/NSCLC.
I guess they figure they were able to make that raise with much less data in hand, so why not now when there is so much more data and promise of more indications to come.